For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.
Posts
Sanofi is the latest company to do some spring cleaning of its pipeline. Thursday morning, the pharma announced it will discontinue two acquired programs in its Q1 update.
The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc. of illegally monopolizing the market with its EpiPen auto-injector, a device used to treat severe allergic reactions.
Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, knocking the German drugmaker’s share price.
Sobi has announced a streamlining and simplification of the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca.
Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.
The U.S. Supreme Court is set to hear a bid by Amgen to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a “blatant attempt” to squeeze competitors out of the market.
Sanofi’s asthma drug Dupixent met all targets in a trial to treat “smoker’s lung”, potentially adding billions to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its bestseller.
The company announced price cuts to Lantus, its most-prescribed insulin product, after similar moves by rivals Novo Nordisk and Eli Lilly and Co.
The buyout will give Sanofi rights over Tzield (teplizumab-mzwv), Provention’s diabetes delay drug, which is the first-ever disease-modifying treatment to delay disease progression.
